S-1: GT Biopharma Files S-1 for Resale of 120 Million Shares Amidst Going Concern and Nasdaq Delisting Concerns

GT Biopharma, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for the resale of up to 120.5 million shares by selling stockholders, while simultaneously addressing a Nasdaq listing compliance issue and disclosing substantial doubt about its ability to continue as a going concern.

Summary

• GT Biopharma, a clinical-stage biopharmaceutical company focused on immuno-oncology, is registering up to 120,553,632 shares of common stock for resale by selling stockholders.
• The company will not receive any direct proceeds from the sale of these shares by the selling stockholders.
• The registered shares include those from a May 2025 private placement (Series L Preferred Stock and warrants) and shares related to a Committed Equity Facility (CEF) entered into in May 2025.
• Under the CEF, the company has the option to sell up to $20 million of its common stock to Facility Investors (Bristol Capital, LLC and Five Narrow Lane, L.P.) at 93% of the volume-weighted average price (VWAP).
• The company received a Nasdaq notification on November 21, 2024, for failing to meet the $2.5 million minimum stockholders' equity requirement.
• A compliance plan was submitted to Nasdaq on December 31, 2024, but Nasdaq has not formally accepted it.
• GT Biopharma believes it has regained Nasdaq compliance on an unaudited proforma basis as of the prospectus date due to the May 2025 private placement.
• The company has raised substantial doubt about its ability to continue as a going concern, stating existing cash resources are insufficient to fund anticipated operations for one year from the December 31, 2024, 10-K filing date.
• As of May 30, 2025, there were 3,147,995 shares of Common Stock outstanding.
• The 25,000,000 shares registered for resale under the CEF represent approximately 89% of the total outstanding shares as of May 30, 2025, if fully issued.
• The closing price of the company's common stock on Nasdaq on June 10, 2025, was $3.04 per share.

Sentiment

Score: 3

Explanation: The filing highlights significant financial distress, including a going concern warning and ongoing Nasdaq delisting risk. While new financing mechanisms are in place, the immediate offering does not provide direct capital to the company, and substantial dilution is a major concern. The positive aspects of the biopharmaceutical platform are overshadowed by the severe financial challenges.

Positives

• The company is a clinical-stage biopharmaceutical company focused on novel immuno-oncology products based on proprietary TriKE and Dual Targeting TriKE platforms, designed to harness and enhance natural killer (NK) cells for cancer treatment.
• Preclinical data suggests the TriKE platform is potentially safer than T-cell immunotherapy due to less cytokine release syndrome (CRS) and fewer neurological complications.
• The TriKE platform is scalable and may be used as both monotherapy and in combination with other standard-of-care therapies, if approved.
• The company has exclusive rights to the TriKE platform and is actively generating additional intellectual property.
• The recent private placement and committed equity facility provide potential avenues for future capital, which is crucial given the company's financial position.
• The company believes it has regained Nasdaq compliance for the minimum stockholders' equity requirement on an unaudited proforma basis due to the May 2025 private placement.

Negatives

• The company has raised substantial doubt about its ability to continue as a going concern, indicating existing cash resources are insufficient to fund operations for one year from the December 31, 2024, 10-K filing date.
• Nasdaq has not formally accepted the company's plan to regain compliance with the minimum stockholders' equity requirement, and delisting remains a significant risk.
• The company will not receive any proceeds from the current offering of 120,553,632 shares, as it is solely for selling stockholders.
• Significant dilution is expected for current shareholders from the conversion and exercise of preferred shares, warrants, and future sales under the Committed Equity Facility (CEF).
• The 25,000,000 shares registered for resale under the CEF represent approximately 89% of the total outstanding shares as of May 30, 2025, indicating substantial potential dilution.
• The company's common stock has historically been deemed a 'penny stock,' subjecting it to marketability restrictions and potentially limiting its ability to raise future capital.
• There is limited research coverage, with only one securities analyst currently covering the company, which could negatively affect trading price and volume.
• The company has never paid dividends and does not anticipate doing so in the foreseeable future, meaning investor returns are solely dependent on stock price appreciation.

Risks

• There has been a limited public market for the Common Stock, and an active trading market may not develop or be sustained, leading to high volatility and wide fluctuations in price.
• It is not possible to predict the actual number of shares or gross proceeds from sales under the Committed Equity Facility (CEF) due to fluctuating market prices and the company's discretion.
• Any issuance and sale of a substantial amount of shares under the CEF could cause additional substantial dilution to shareholders.
• Investors buying shares from Facility Investors at different times will likely pay different prices and may experience different levels of dilution and investment outcomes.
• Future sales under the CEF at prices lower than those paid by current investors could cause a decline in the value of their shares.
• The actual sales of shares or the mere existence of the CEF arrangement may make it more difficult for the company to sell equity or equity-related securities in the future.
• The company has broad discretion over the use of proceeds from CEF sales, which may not align with investor expectations or yield significant returns.
• The large number of outstanding warrants (16,726,669 shares) and options (124,600 shares) may adversely impact the ability to raise capital and affect stock price and liquidity, and their exercise will have a dilutive effect.
• The Common Stock may be deemed a low-priced penny stock, subjecting it to marketability restrictions and potentially limiting future capital raises.
• FINRA sales practice requirements may make it more difficult for broker-dealers to recommend the Common Stock, which could depress its price.
• Limited or no research coverage by securities or industry analysts could negatively affect the trading price and volume.
• Delaware law and the company's corporate documents contain anti-takeover provisions that could discourage, delay, or prevent an acquisition, potentially causing the stock price to decline.
• The company does not intend to pay dividends, limiting investor returns to stock price appreciation.
• The company needs substantial additional capital to fund operations and product development, and securing this funding on acceptable terms is uncertain.
• Substantial doubt exists about the company's ability to continue as a going concern, with existing cash resources insufficient for one year of operations.
• Failure to maintain Nasdaq listing requirements, particularly the minimum stockholders' equity, could lead to delisting, adversely affecting liquidity and market price.
• Market data and industry statistics incorporated by reference are based on independent publications, and their accuracy or completeness is not guaranteed.

Future Outlook

The company expects to need substantial additional capital resources to develop its product candidates and launch commercialization. Its ability to secure this financing on acceptable terms is uncertain, and failure to do so could force delays, reductions, or elimination of research and product development initiatives. The company does not anticipate paying any cash dividends in the foreseeable future, intending to retain future earnings for business development and expansion.

Management Comments

• "We believe our TriKE and Dual Targeting TriKE platforms that activate endogenous NK cells are potentially safer than T-cell immunotherapy because there is less cytokine release syndrome (CRS) and fewer neurological complications."
• "We are using our TriKE platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic malignancies, solid tumors, and potentially autoimmune disorders."
• "We believe our TriKEs may have the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies."
• "As a result of the Private Placement that occurred on May 12, 2025, the Company believes it has stockholders equity on an unaudited proforma basis of at least $2.5 million as of the date of this prospectus."
• "While it is very difficult to estimate our future liquidity requirements, we believe if we are unable to obtain additional financing, existing cash resources will not be sufficient to enable us to fund the anticipated level of our operations through one year from the date the financial statements included in our annual report on Form 10-K for the year ended December 31, 2024 were issued."

Industry Context

GT Biopharma operates in the highly competitive and capital-intensive immuno-oncology sector, specifically focusing on novel immune cell engager technologies like TriKE and Dual Targeting TriKE platforms. These platforms aim to leverage natural killer (NK) cells for treating hematologic malignancies, solid tumors, and potentially autoimmune disorders, positioning the company within the growing field of cell-based therapies. The company's emphasis on potentially lower cytokine release syndrome (CRS) and neurological complications compared to T-cell immunotherapy highlights a strategic differentiation point within the industry, addressing known challenges in existing treatments. However, as a clinical-stage biopharmaceutical company, it faces significant R&D costs, regulatory hurdles, and the need for substantial ongoing financing, typical challenges for companies in this stage of drug development.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Significant potential for dilution due to the large number of shares being registered for resale and future sales under the Committed Equity Facility. Existing shareholders' economic and voting interests will be diluted. The 'going concern' warning and Nasdaq delisting risk pose substantial threats to the value and liquidity of their investment.
• **Investors (Purchasers in this offering)**: Will experience immediate and substantial dilution in the book value of their investment. Those purchasing from Facility Investors at different times may pay different prices and experience varying levels of dilution.
• **Employees**: The 'going concern' warning indicates potential instability that could impact job security and future prospects.
• **Creditors**: The 'going concern' warning suggests increased risk regarding the company's ability to meet its financial obligations.

Next Steps

• Company to file a further amendment to the registration statement to delay its effective date until specifically stated or determined by the SEC.
• Company to file a resale registration statement for the private placement shares and warrants not later than 30 calendar days after May 12, 2025, and after each Greenshoe Right exercise, to become effective no later than 90 days after filing.
• Nasdaq will continue to monitor the company's compliance with the Minimum Stockholders Equity Requirement.
• Company to seek stockholder approval at its Annual Meeting on July 24, 2025, for the removal of Beneficial Ownership Limitation and Exchange Cap related to Series L Preferred Stock conversion.
• Company may elect to sell shares to Facility Investors under the Committed Equity Facility from time to time until the first day of the month next following the 36-month period from the Commencement Date.
• If the company decides to sell more than 25,000,000 shares under the CEF, it must first file additional registration statements with the SEC.

Key Dates

Recommendation

Keywords

GT Biopharma, GTBP, S-1 Filing, SEC Filing, Biopharmaceutical, Immuno-oncology, TriKE, Dual Targeting TriKE, Natural Killer Cells, NK Cells, Cancer Treatment, Hematologic Malignancies, Solid Tumors, Autoimmune Disorders, Committed Equity Facility, CEF, Private Placement, Warrants, Preferred Stock, Nasdaq Listing, Delisting Risk, Going Concern, Dilution, Capital Raise, Biotech, Clinical Stage, Oncology